• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

循环基质溶解素-1(基质金属蛋白酶-3):急性心肌梗死后左心室功能障碍、重塑及全因死亡率的新型预测指标。

Circulating stromelysin-1 (MMP-3): a novel predictor of LV dysfunction, remodelling and all-cause mortality after acute myocardial infarction.

作者信息

Kelly D, Khan S, Cockerill G, Ng L L, Thompson M, Samani N J, Squire I B

机构信息

Department of Cardiovascular Sciences, University of Leicester, UK.

出版信息

Eur J Heart Fail. 2008 Feb;10(2):133-9. doi: 10.1016/j.ejheart.2007.12.009. Epub 2008 Jan 30.

DOI:10.1016/j.ejheart.2007.12.009
PMID:18234553
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2635532/
Abstract

INTRODUCTION

Changes to cardiac matrix are central to ventricular remodelling after acute MI and matrix metalloproteinase expression is implicated in this process. We investigated the temporal profile of MMP-3 and its relationship to LV dysfunction and prognosis following AMI.

METHODS

We studied 382 patients with AMI. Plasma MMP-3 was measured at 0-12, 12-24 h and for subsequent 24 h periods during admission. LV function (LVEF) was assessed by echocardiography pre-discharge and at a median of 148 days and clinical endpoints at a median of 313 days.

RESULTS

MMP-3 peaked prior to discharge thus pre-discharge levels were used in analyses. MMP-3 was associated with patient age (p<0.001), creatinine (p<0.001) and was higher in males (p<0.001) and hypertensives (p<0.001). MMP-3 inversely correlated with LVEF at follow-up (p=0.043), was higher in subjects with LVEF <40% (p=0.017) and in subjects with increasing EDV (p=0.017) or ESV (p=0.007) compared to those in whom volumes fell between visits. In the 58 patients reaching the endpoint of death or heart failure, MMP-3 was higher (p<0.001). On Kaplan-Meier analysis, subjects with levels above optimum cut off identified via ROC curves were more likely to suffer a clinical event (p=0.037).

CONCLUSION

MMP-3 is associated with left ventricular dysfunction, adverse left ventricular remodelling and prognosis after AMI.

摘要

引言

急性心肌梗死后心脏基质的变化是心室重构的核心,基质金属蛋白酶的表达参与了这一过程。我们研究了基质金属蛋白酶-3(MMP-3)的时间变化情况及其与急性心肌梗死后左心室功能障碍和预后的关系。

方法

我们研究了382例急性心肌梗死患者。入院期间在0 - 12小时、12 - 24小时以及随后的24小时时间段测量血浆MMP-3。出院前、中位数为148天时通过超声心动图评估左心室功能(左心室射血分数),中位数为313天时评估临床终点。

结果

MMP-3在出院前达到峰值,因此分析中使用出院前水平。MMP-3与患者年龄(p<0.001)、肌酐(p<0.001)相关,在男性(p<0.001)和高血压患者(p<0.001)中更高。随访时MMP-3与左心室射血分数呈负相关(p = 0.043),与左心室射血分数<40%的患者相比更高(p = 0.017),与随访期间左心室舒张末期容积(EDV)增加(p = 0.017)或左心室收缩末期容积(ESV)增加(p = 0.007)的患者相比更高,而与那些容积下降的患者相比。在58例达到死亡或心力衰竭终点的患者中,MMP-3更高(p<0.001)。根据Kaplan-Meier分析,通过ROC曲线确定的高于最佳临界值水平的患者更有可能发生临床事件(p = 0.037)。

结论

MMP-3与急性心肌梗死后左心室功能障碍、不良左心室重构和预后相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e336/2635532/6a0be8d416f6/nihms-1382-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e336/2635532/7749eb7fb51b/nihms-1382-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e336/2635532/4ae499bc4d1f/nihms-1382-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e336/2635532/6a0be8d416f6/nihms-1382-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e336/2635532/7749eb7fb51b/nihms-1382-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e336/2635532/4ae499bc4d1f/nihms-1382-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e336/2635532/6a0be8d416f6/nihms-1382-f0004.jpg

相似文献

1
Circulating stromelysin-1 (MMP-3): a novel predictor of LV dysfunction, remodelling and all-cause mortality after acute myocardial infarction.循环基质溶解素-1(基质金属蛋白酶-3):急性心肌梗死后左心室功能障碍、重塑及全因死亡率的新型预测指标。
Eur J Heart Fail. 2008 Feb;10(2):133-9. doi: 10.1016/j.ejheart.2007.12.009. Epub 2008 Jan 30.
2
Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study.血浆基质金属蛋白酶-9与人类急性心肌梗死后左心室重构:一项前瞻性队列研究。
Eur Heart J. 2007 Mar;28(6):711-8. doi: 10.1093/eurheartj/ehm003. Epub 2007 Mar 5.
3
Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction.血浆组织金属蛋白酶抑制剂-1 和基质金属蛋白酶-9:急性心肌梗死后左心室重构和预后的新指标。
Eur Heart J. 2008 Sep;29(17):2116-24. doi: 10.1093/eurheartj/ehn315. Epub 2008 Jul 8.
4
C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical heart failure in survivors of myocardial infarction.C 端前血管加压素( copeptin )与心肌梗死幸存者的左心室功能障碍、重塑及临床心力衰竭相关。
J Card Fail. 2008 Nov;14(9):739-45. doi: 10.1016/j.cardfail.2008.07.231. Epub 2008 Aug 30.
5
Plasma MMP-2, MMP-9 and N-BNP in long-term survivors following complicated myocardial infarction: relation to cardiac magnetic resonance imaging measures of left ventricular structure and function.复杂心肌梗死后长期存活者的血浆基质金属蛋白酶-2、基质金属蛋白酶-9和N末端脑钠肽前体:与左心室结构和功能的心脏磁共振成像测量的关系
J Card Fail. 2007 Dec;13(10):843-9. doi: 10.1016/j.cardfail.2007.07.006.
6
Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction.急性心肌梗死后人体血浆基质金属蛋白酶-9和基质金属蛋白酶-2:与左心室功能障碍的超声心动图及神经体液参数的相关性
J Card Fail. 2004 Aug;10(4):328-33. doi: 10.1016/j.cardfail.2003.11.003.
7
Interleukin-21--a biomarker of importance in predicting myocardial function following acute infarction?白细胞介素-21--预测急性心肌梗死后心肌功能的重要标志物?
Cytokine. 2012 Oct;60(1):220-5. doi: 10.1016/j.cyto.2012.06.002. Epub 2012 Jun 27.
8
Serum MMP-8: a novel indicator of left ventricular remodeling and cardiac outcome in patients after acute myocardial infarction.血清 MMP-8:急性心肌梗死后患者左心室重构和心脏结局的新指标。
PLoS One. 2013 Aug 14;8(8):e71280. doi: 10.1371/journal.pone.0071280. eCollection 2013.
9
Predictive utility of the changes in matrix metalloproteinase-2 in the early phase for left ventricular reverse remodeling after an acute myocardial infarction.急性心肌梗死后早期基质金属蛋白酶-2变化对左心室逆向重构的预测效用
J Am Heart Assoc. 2015 Jan 23;4(1):e001359. doi: 10.1161/JAHA.114.001359.
10
Early measurements of plasma matrix metalloproteinase-2 predict infarct size and ventricular dysfunction in ST-elevation myocardial infarction.早期测量血浆基质金属蛋白酶-2 可预测 ST 段抬高型心肌梗死的梗死面积和心室功能障碍。
Heart. 2012 Jan;98(1):31-6. doi: 10.1136/heartjnl-2011-300079. Epub 2011 Jul 4.

引用本文的文献

1
Sex-specific cardiovascular protein levels and their link with clinical outcome in heart failure.心力衰竭中心血管蛋白的性别特异性水平及其与临床结局的关系。
ESC Heart Fail. 2024 Feb;11(1):594-600. doi: 10.1002/ehf2.14578. Epub 2023 Nov 27.
2
Matrix Metalloproteinases and Heart Transplantation-A Pathophysiological and Clinical View.基质金属蛋白酶与心脏移植:病理生理学与临床观察
Medicina (Kaunas). 2023 Jul 13;59(7):1295. doi: 10.3390/medicina59071295.
3
Matrix metalloproteinases in coronary artery disease and myocardial infarction.

本文引用的文献

1
Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study.血浆基质金属蛋白酶-9与人类急性心肌梗死后左心室重构:一项前瞻性队列研究。
Eur Heart J. 2007 Mar;28(6):711-8. doi: 10.1093/eurheartj/ehm003. Epub 2007 Mar 5.
2
Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling.心肌梗死后患者体内基质金属蛋白酶释放具有特定的时间模式:与左心室重构的关系。
Circulation. 2006 Sep 5;114(10):1020-7. doi: 10.1161/CIRCULATIONAHA.105.600353. Epub 2006 Aug 21.
3
基质金属蛋白酶与冠状动脉疾病和心肌梗死。
Basic Res Cardiol. 2023 May 9;118(1):18. doi: 10.1007/s00395-023-00987-2.
4
Extracellular Matrix Remodeling Biomarkers in Coronary Artery Disease.冠状动脉疾病中的细胞外基质重塑生物标志物
Curr Top Med Chem. 2022;22(28):2355-2367. doi: 10.2174/1568026623666221024091758.
5
Cluster analysis of extracellular matrix biomarkers predicts the development of impaired systolic function within 1 year of acute myocardial infarction.细胞外基质生物标志物聚类分析可预测急性心肌梗死后 1 年内收缩功能障碍的发展。
Heart Vessels. 2022 Dec;37(12):2029-2038. doi: 10.1007/s00380-022-02118-8. Epub 2022 Jul 27.
6
Physical Inactivity Is Associated With Post-discharge Mortality and Re-hospitalization Risk Among Swedish Heart Failure Patients-The HARVEST-Malmö Study.身体活动不足与瑞典心力衰竭患者出院后死亡率及再住院风险相关——哈维斯-马尔默研究
Front Cardiovasc Med. 2022 Feb 21;9:843029. doi: 10.3389/fcvm.2022.843029. eCollection 2022.
7
A combined biomarker approach for characterising extracellular matrix profiles in acute myocardial infarction.一种联合生物标志物方法,用于描述急性心肌梗死细胞外基质特征。
Sci Rep. 2021 Jun 16;11(1):12705. doi: 10.1038/s41598-021-92108-z.
8
Sex differences in circulating proteins in heart failure with preserved ejection fraction.射血分数保留的心力衰竭患者循环蛋白中的性别差异。
Biol Sex Differ. 2020 Aug 24;11(1):47. doi: 10.1186/s13293-020-00322-7.
9
Expression of Nik-related kinase in smooth muscle cells attenuates vascular inflammation and intimal hyperplasia.Nik 相关激酶在平滑肌细胞中的表达可减轻血管炎症和内膜增生。
Aging (Albany NY). 2020 Apr 24;12(8):7511-7533. doi: 10.18632/aging.103104.
10
Structural studies of the MMP-3 interaction with triple-helical collagen introduce new roles for the enzyme in tissue remodelling.基质金属蛋白酶-3 与三螺旋胶原相互作用的结构研究为该酶在组织重塑中的新作用提供了线索。
Sci Rep. 2019 Dec 11;9(1):18785. doi: 10.1038/s41598-019-55266-9.
Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial.
选择性基质金属蛋白酶抑制剂(PG-116800)预防心肌梗死后心室重构的效果:PREMIER(心肌梗死早期重构预防)试验结果
J Am Coll Cardiol. 2006 Jul 4;48(1):15-20. doi: 10.1016/j.jacc.2006.02.055. Epub 2006 Jun 21.
4
Differential expression of MMPs and TIMPs in moderate and severe heart failure in a transgenic model.基质金属蛋白酶(MMPs)和基质金属蛋白酶组织抑制因子(TIMPs)在转基因模型中中度和重度心力衰竭中的差异表达
J Card Fail. 2006 May;12(4):314-25. doi: 10.1016/j.cardfail.2006.01.009.
5
Contribution of plasma matrix metalloproteinases to development of left ventricular hypertrophy and diastolic dysfunction in hypertensive subjects.血浆基质金属蛋白酶在高血压患者左心室肥厚和舒张功能障碍发生中的作用。
Tohoku J Exp Med. 2006 Feb;208(2):117-22. doi: 10.1620/tjem.208.117.
6
Comparison of levels of matrix metalloproteinase-2 and -3 in patients with ischemic cardiomyopathy versus nonischemic cardiomyopathy.缺血性心肌病患者与非缺血性心肌病患者基质金属蛋白酶-2和-3水平的比较。
Am J Cardiol. 2005 Nov 15;96(10):1449-51. doi: 10.1016/j.amjcard.2005.06.096. Epub 2005 Sep 29.
7
Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.循环中的基质金属蛋白酶-2而非基质金属蛋白酶-3、基质金属蛋白酶-9或金属蛋白酶组织抑制剂-1可预测充血性心力衰竭患者的预后。
Am Heart J. 2005 Sep;150(3):484-7. doi: 10.1016/j.ahj.2004.11.016.
8
Regulation of matrix metalloproteinases and their inhibitors in the left ventricular myocardium of patients with aortic stenosis.主动脉瓣狭窄患者左心室心肌中基质金属蛋白酶及其抑制剂的调节
J Mol Med (Berl). 2004 Dec;82(12):809-20. doi: 10.1007/s00109-004-0606-4. Epub 2004 Nov 19.
9
Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction.急性心肌梗死后人体血浆基质金属蛋白酶-9和基质金属蛋白酶-2:与左心室功能障碍的超声心动图及神经体液参数的相关性
J Card Fail. 2004 Aug;10(4):328-33. doi: 10.1016/j.cardfail.2003.11.003.
10
Prognostic impact of matrix metalloproteinase gene polymorphisms in patients with heart failure according to the aetiology of left ventricular systolic dysfunction.根据左心室收缩功能障碍的病因,基质金属蛋白酶基因多态性对心力衰竭患者的预后影响。
Eur Heart J. 2004 Apr;25(8):688-93. doi: 10.1016/j.ehj.2004.01.015.